Myxina (Nimesulide)

Nimesulide selectively inhibits the cyclooxygenase‑2 (COX‑2) enzyme, which converts arachidonic acid into prostaglandins that mediate pain, fever and inflammation. By blocking COX‑2, the drug lowers prostaglandin levels at the site of injury, providing analgesic and anti‑inflammatory effects while sparing COX‑1 activity.

The appropriate dose of Myxina is determined by the prescribing healthcare professional based on the patient’s age, clinical condition, and response to therapy. The prescriber will select the strength and dosing schedule that best balances efficacy with safety, following local regulatory guidelines.

Safety of nimesulide in pregnancy and lactation has not been established, and the drug is generally avoided in these populations unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatments with their healthcare provider.

To place an order, submit an enquiry on the Myxina product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑selective NSAIDs such as ibuprofen, nimesulide offers relatively greater COX‑2 selectivity, which may reduce gastrointestinal side effects in some patients. However, it carries its own risk profile, including potential hepatic effects, and should be chosen based on individual patient factors and physician judgment.

Myxina should be stored at ambient temperature below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Myxina is taken orally, usually with a full glass of water. It may be taken with or without food, although taking it with meals can help lessen gastrointestinal discomfort. Patients should follow the dosing instructions provided by their prescriber.

The most serious adverse reactions include severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and significant renal impairment. Patients should be monitored for signs of hepatic dysfunction, rash, or decreased urine output, and the drug should be discontinued immediately if such events occur.

Myxina is contraindicated in individuals with known hypersensitivity to nimesulide or other NSAIDs, those with active peptic ulcer disease, severe hepatic or renal impairment, and patients receiving other COX‑2 inhibitors. It should also be avoided in pregnant women unless absolutely necessary.